# A Study to Compare Safety and Efficacy of High Doses of Eteplirsen in Participants With Duchenne Muscular Dystrophy (DMD) (MIS51ON)

> **NCT03992430** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Sarepta Therapeutics, Inc.** · enrollment: 160 (actual)

## Conditions studied

- Muscular Dystrophy, Duchenne

## Interventions

- **DRUG:** Eteplirsen

## Key facts

- **NCT ID:** NCT03992430
- **Lead sponsor:** Sarepta Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2020-07-13
- **Primary completion:** 2026-10-31
- **Final completion:** 2026-10-31
- **Target enrollment:** 160 (ACTUAL)
- **Last updated:** 2026-02-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03992430

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03992430, "A Study to Compare Safety and Efficacy of High Doses of Eteplirsen in Participants With Duchenne Muscular Dystrophy (DMD) (MIS51ON)". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03992430. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*